国际肿瘤学杂志

国际肿瘤学杂志 ›› 2019, Vol. 46 ›› Issue (10): 581-584.doi: 10.3760/cma.j.issn.1673-422X.2019.10.002

• 论著 • 上一篇    下一篇

乳腺癌患者组织及血清中EGFL7、P185蛋白的检测及临床意义

胡小波,夏明智,何悦,刘志华   

  1. 湖南省肿瘤医院乳腺外一科，长沙410000

  • 出版日期:2019-10-08 发布日期:2019-12-20
  • 通讯作者: 胡小波，Email: hxb6747@163.com E-mail:hxb6747@163.com

Detection and clinical significance of EGFL7 and P185 protein in tissues and serum of patients with breast cancer

Hu Xiaobo, Xia Mingzhi, He Yue, Liu Zhihua   

  1. First Department of Breast Surgery, Hunan Cancer Hospital, Changsha 410000, China

  • Online:2019-10-08 Published:2019-12-20
  • Contact: Hu Xiaobo, Email: hxb6747@163.com E-mail:hxb6747@163.com

PDF

189

摘要： 目的  检测表皮生长因子样结构域-7（EGFL7）及P185蛋白在乳腺癌患者癌组织及血清中的水平，分析其在组织中的表达水平与患者临床病理特征的关系。方法  收集2016年3月至2018年3月在湖南省肿瘤医院就诊的60例乳腺癌患者为研究对象（观察组），同时选取同期来湖南省肿瘤医院就诊的乳腺良性病变患者60例为对照组。利用免疫组织化学二步法检测两组患者组织中EGFL7及P185蛋白的表达，利用酶联免疫吸附法（ELISA）检测两组患者血清中EGFL7及P185蛋白的水平。分析EGFL7及P185蛋白表达与乳腺癌患者临床病理特征的关系。结果  观察组和对照组患者组织中EGFL7阳性表达率分别为65.00%（39/60）、28.33%（17/60），差异具有统计学意义（χ2=16.205，P＜0.001）；两组患者P185阳性表达率分别为43.33%（26/60）、15.00%（9/60），差异具有统计学意义（χ2=11.657，P=0.001）。观察组和对照组患者血清中EGFL7蛋白水平分别为（3.39±0.38）μg/ml、（2.75±0.31）μg/ml，差异具有统计学意义（t=10.109，P＜0.001）；两组患者血清中P185蛋白水平分别为（7.12±0.75）μg/ml、（6.08±0.62）μg/ml，差异具有统计学意义（t=8.279，P＜0.001）。EGFL7阳性表达与肿瘤大小（χ2=6.128，P=0.013）、TNM分期（χ2=7.781，P=0.005）、淋巴结有无转移（χ2=5.444，P=0.020）密切相关；P185阳性表达与肿瘤大小（χ2=8.910，P=0.003）、TNM分期（χ2=8.024，P=0.005）密切相关。结论   EGFL7及P185蛋白在乳腺癌组织及血清中的水平较高，且其阳性表达均与肿瘤大小及TNM分期有关。EGFL7及P185蛋白在乳腺癌疾病进程中有重要作用。

关键词: 乳腺肿瘤, 表皮生长因子样结构域-7

Abstract: Objective  To detect the expressions of epidermal growth factor-like domain 7 (EGFL7) and P185 protein in breast cancer tissues and serum, and to analyze the correlation between the expression levels of EGFL7 and P185 in tissues and clinicopathological parameters of breast cancer patients. Methods  Sixty patients with breast cancer in Hunan Cancer Hospital from March 2016 to March 2018 were collected as observation group, and 60 patients with breast benign lesions in the hospital during the same period were selected as control group. The expressions of EGFL7 and P185 protein in tissues of patients in the two groups were detected by immunohistochemical two-step method, and the levels of EGFL7 and P185 protein in serum of patients in the two groups were detected by enzyme-linked immunosorbent assay (ELISA). The relationships between the expressions of EGFL7 and P185 protein and clinicopathological parameters of breast cancer patients were analyzed. Results  The positive rates of EGFL7 in tissues in the observation group and the control group were 65.00% (39/60) and 28.33% (17/60), and there was a significant difference between the two groups (χ2=16.205, P＜0.001). The positive rates of P185 in tissues in the two groups were 43.33% (26/60) and 15.00% (9/60), and there was a significant difference between the two groups (χ2=11.657,P=0.001). The serum levels of EGFL7 protein in the observation group and the control group were (3.39±0.38) μg/ml and (2.75±0.31) μg/ml respectively, with a significant difference (t=10.109, P<0.001). The serum levels of P185 protein in the two groups were (7.12±0.75) μg/ml and (6.08±0.62) μg/ml respectively, with a significant difference (t=8.279, P<0.001). The positive expression of EGFL7 protein was closely related to tumor size (χ2=6.128, P=0.013), TNM stage (χ2=7.781,P=0.005) and metastasis (χ2=5.444, P=0.020). The positive expression of P185 protein was closely related to tumor size (χ2=8.910, P=0.003) and TNM stage (χ2=8.024, P=0.005). Conclusion  The levels of EGFL7 and P185 protein are high in breast cancer tissues and serum, and their positive expressions are related to tumor size and TNM stage. EGFL7 and P185 proteins play important roles in the progression of breast cancer.

Key words: Breast neoplasms, Epidermal growth factor-like domain 7, P185